Clarke P, Khan AM, Kamdar N, Seiler K, Latham-Mintus K, Peterson MD, Meade MA, Ehrlich JR. Risk of type 2 diabetes mellitus among adults aging with vision impairment: the role of the neighborhood environment. Disabil Health J. 2023 Jan;16(1):101371. doi: 10.1016/j.dhjo.2022.101371
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Dickey H, Ikenwilo D, Norwood P, Watson V, Zangelidis A. Utilisation of eye-care services: the effect of Scotland's free eye examination policy. Health Policy (New York). 2012 Dec;108(2-3):286-93. doi: 10.1016/j.healthpol.2012.09.006
Watson V, Sussex J, Ryan M, Tetteh E. Managing poorly performing clinicians: health care providers' willingness to pay for independent help. Health Policy (New York). 2012 Mar;104(3):260-71. doi: 10.1016/j.healthpol.2011.12.006
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X